SAN Sanofi

Sanofi :  INFORMATION ON THE FINAL TERMS OF DEPARTURE OF OLIVIER BRANDICOURT, FORMER CHIEF EXECUTIVE OFFICER

Sanofi :  INFORMATION ON THE FINAL TERMS OF DEPARTURE OF OLIVIER BRANDICOURT, FORMER CHIEF EXECUTIVE OFFICER

 PRESS RELEASE

 INFORMATION ON THE FINAL TERMS OF DEPARTURE OF OLIVIER BRANDICOURT, FORMER CHIEF EXECUTIVE OFFICER

Paris, on April 28, 2020

Given the shareholders’ vote on Olivier Brandicourt’s compensation for fiscal year 2019 during the General Meeting held today and following the Board of Directors’ meeting held after the Shareholders’ Meeting, Sanofi discloses the final terms of departure of Olivier Brandicourt, former Chief Executive Officer, in office until August 31, 2019.

Fixed compensation

The fixed compensation of Olivier Brandicourt with respect to financial year 2019 amounted to 800,000 euros. It was apportioned on a time basis from January 1, 2019 through August 31, 2019, the date of his departure from office as Chief Executive Officer.

Variable compensation

Given the rejection of the 19th resolution and pursuant to the provisions of the second paragraph of Article L. 225-100 III of the French Commercial Code, the variable compensation of Olivier Brandicourt for the period January 1, 2019 to August 31, 2019, set at 1,161,000 euros (amount apportioned on a time basis) after review of the level of attainment of the performance conditions by the Board of Directors in its March 4, 2020 meeting, will not be paid.

Top-up defined benefit pension rights

As a reminder, the vesting of the contingent rights under the top-up benefit pension plan to which Olivier Brandicourt was entitled on retirement was subject to a performance condition related to the attainment level of the variable portion of the Chief Executive Officer’s compensation.

Given the rejection of the 19th resolution, the benefits that Olivier Brandicourt will receive under the top-up pension scheme will integrate the rights acquired until December 31, 2018. Consequently, the final amount of the top-up pension is 501,241 euros per year, or 20.6150% of his reference compensation (capped at 60 times the annual French social security ceiling, representing a cap of €2,431,440 in 2019).

As a reminder, in accordance with the Compensation policy for the Chief Executive Officer, payment of this top-up pension is separate from any other termination benefit or non-compete indemnity.

Ongoing equity-based compensation plans

Pursuant to the compensation policy for the Chief Executive Officer which provides for a continuation of rights in the event of retirement, the Board of Directors had confirmed the retention of the rights of Olivier Brandicourt under stock option plans and performance share plans that have not yet vested.

As a reminder, the options and performance shares initially granted remain bound by the terms of the plans, including performance and non-competition conditions.  

***

 

Attachment

EN
28/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release:  Sanofi’s Board of Directors proposes the appointment o...

Press Release:  Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director  Paris, March 5, 2026. The Board of Directors of Sanofi has decided to propose, at the next Annual General Meeting of shareholders scheduled for April 29, 2026, the appointment of Christel Heydemann as an independent director, as well as the renewal of the mandates of Christophe Babule and Jean-Paul Kress.  Patrick Kron, independent director and Chairman of the Nomination,...

 PRESS RELEASE

Communiqué de presse : Le Conseil d’administration de Sanofi propose l...

Communiqué de presse : Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante   Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante  Paris, le 5 mars 2026. Le Conseil d’administration de Sanofi a décidé de proposer, dans le cadre de la prochaine Assemblée générale des actionnaires prévue le 29 avril 2026, la nomination de Christel Heydemann en qualité d’administratrice indépendante et le renouvellement des mandats de Christophe Babule et Jean-P...

 PRESS RELEASE

Press Release: Filing of an amendment to the French “Document d’Enregi...

Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). This amendment notably includes additions to the report on corporate governance established in accordance with French law. ...

 PRESS RELEASE

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrem...

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Paris, le 4 mars 2026. Sanofi annonce avoir déposé ce jour un amendement à son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France. Cet amendement intègre notamment des compléments au (i) rapport de gestion et au (ii) rapport sur le gouvernement d’entreprise. Le document pe...

 PRESS RELEASE

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in...

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RDThird global orphan drug designation for rilzabrutinib in IgG4-RD, underpinning Sanofi’s commitment to rare immune-mediated diseases Paris, March 2, 2026 – The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch